Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionRhumbline Advisers
Latest Disclosed Ownership195,277 shares
Latest Disclosed Value $ 64,611,243
Rhumbline Advisers reports 0.01% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - Rhumbline Advisers filed a 13F-HR form disclosing ownership of 195,277 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $55,790,639 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 195,266 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.01% during the quarter. The current value of the position is $50,869,658 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 195,277 11 0.01 64,611 -16.79 0.0553
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 195,266 -1,231 -0.63 77,647 -13.34 0.0628
2025-11-06 2025-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 196,497 -3,988 -1.99 89,603 37.06 0.0720
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 200,485 19,022 10.48 65,376 33.43 0.0560
2025-05-29 2025-03-31 13F/A-1 ALNYLAM PHARMACEUTL COM 02043Q107 181,463 1,885 1.05 48,999 15.96 0.0458
2025-04-08 2025-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 181,463 1,885 48,999 0.0458
2025-05-29 2024-12-31 13F/A-1 ALNYLAM PHARMACEUTL COM 02043Q107 179,578 -1,850 -1.02 42,256 -15.32 0.0378
2025-01-30 2024-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 179,578 -1,850 42,256 0.0378
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 181,428 8,101 4.67 49,898 18.47 0.0450
2024-08-01 2024-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 173,327 -362 -0.21 42,118 62.26 0.0396
2024-05-09 2024-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 173,689 816 0.47 25,958 -21.55 0.0249
2024-02-08 2023-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 172,873 802 0.47 33,090 8.58 0.0347
2023-11-09 2023-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 172,071 -3,263 -1.86 30,474 -8.49 0.0354
2023-08-08 2023-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 175,334 17,439 11.04 33,303 107,325.81 0.0373
2023-05-11 2023-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 157,895 9,499 6.40 32 -99.91 0.0390
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 148,396 11,711 8.57 35,266 28.90 0.0474
2022-11-10 2022-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 136,685 8,174 6.36 27,359 45.97 0.0408
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 128,511 12,634 10.90 18,743 -0.95 0.0274
2022-05-12 2022-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 115,877 -3,955 -3.30 18,922 -6.88 0.0244
2022-02-10 2021-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 119,832 3,723 3.21 20,321 -7.31 0.0249
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 116,109 -306 -0.26 21,923 11.09 0.0297
2021-08-05 2021-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 116,415 -5,608 -4.60 19,735 14.55 0.0259
2021-05-06 2021-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 122,023 -4,549 -3.59 17,228 4.72 0.0234
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 126,572 -7,326 -5.47 16,451 -15.62 0.0227
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 133,898 -6,577 -4.68 19,496 -6.30 0.0305
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 140,475 28,498 25.45 20,806 70.69 0.0347
2020-05-06 2020-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 111,977 5,872 5.53 12,189 -0.25 0.0255
2020-02-05 2019-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 106,105 3,059 2.97 12,220 47.46 0.0204
2019-10-23 2019-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 103,046 -9 -0.01 8,287 10.82 0.0151
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 103,055 10,164 10.94 7,478 -13.86 0.0140
2019-05-01 2019-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 92,891 2,295 2.53 8,681 31.43 0.0168
2019-01-31 2018-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 90,596 -5,849 -6.06 6,605 -21.75 0.0144
2018-11-07 2018-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 96,445 -1,501 -1.53 8,441 -12.50 0.0163
2018-08-06 2018-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 97,946 2,591 2.72 9,647 -15.06 0.0195
2018-05-02 2018-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 95,355 -4,560 -4.56 11,357 -10.53 0.0237
2018-02-09 2017-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 99,915 7,347 7.94 12,694 16.72 0.0258
2017-11-06 2017-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 92,568 1,346 1.48 10,876 49.48 0.0236
2017-08-02 2017-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 91,222 -3,189 -3.38 7,276 50.36 0.0166
2017-05-02 2017-03-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 94,411 4,028 4.46 4,839 43.00 0.0113
2017-01-27 2016-12-31 13F ALNYLAM PHARMACEUTL COM 02043Q107 90,383 7,712 9.33 3,384 -39.60 0.0086
2016-11-08 2016-09-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 82,671 2,407 3.00 5,603 25.80 0.0154
2016-08-11 2016-06-30 13F ALNYLAM PHARMACEUTL COM 02043Q107 80,264 4,740 6.28 4,454 -6.05 0.0132
2016-05-02 2016-03-31 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 75,524 -150 -0.20 4,741 -33.45 0.0147
2016-02-03 2015-12-31 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 75,674 2,053 2.79 7,124 20.42 0.0229
2015-11-04 2015-09-30 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 73,621 3,281 4.66 5,916 -29.84 0.0201
2015-08-04 2015-06-30 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 70,340 11,510 19.56 8,432 37.26 0.0269
2015-05-12 2015-03-31 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 58,830 5,081 9.45 6,143 17.82 0.0177
2015-02-06 2014-12-31 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 53,749 -131 -0.24 5,214 23.91 0.0151
2014-11-12 2014-09-30 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 53,880 -308 -0.57 4,208 22.93 0.0126
2014-08-06 2014-06-30 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 54,188 -8,952 -14.18 3,423 -19.25 0.0100
2014-05-06 2014-03-31 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 63,140 -2,860 -4.33 4,239 -0.16 0.0126
2014-02-03 2013-12-31 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 66,000 2,140 3.35 4,246 3.86 0.0125
2013-11-05 2013-09-30 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 63,860 679 1.07 4,088 108.68 0.0127
2013-08-07 2013-06-30 13F ALNYLAM PHARMACEUTICALS INC COM 02043Q107 63,181 63,181 1,959 0.0063
2013-08-07 2013-06-30 13F ALFA S.A.B. DE C.V. COM 002043423 219,700 156,519 527 0.0017
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.